EC approves AbbVie’s Tepkinly combination for follicular lymphoma

The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. The decision is based on data from the pivotal Phase III EPCORE FL-1 trial. Epcoritamab is co-developed by AbbVie and Genmab. Credit: © AbbVie Inc. All rights reserved. The European Commission (EC) has granted marketing authorisation for AbbVie’s Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R²) for adult patients with relapsed or refractory follicular lymphoma. The decision is based on data from the pivotal Phase III EPCORE FL-1 trial, which assessed the efficacy and…

Source: Pharmaceutical Technology